Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7878603rdf:typepubmed:Citationlld:pubmed
pubmed-article:7878603lifeskim:mentionsumls-concept:C0232197lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0151744lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0003195lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0449864lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0040223lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0013790lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0442828lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C0332162lld:lifeskim
pubmed-article:7878603lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:7878603pubmed:issue4lld:pubmed
pubmed-article:7878603pubmed:dateCreated1995-4-6lld:pubmed
pubmed-article:7878603pubmed:abstractTextIn recent clinical studies, certain class I antiarrhythmic drugs (flecaïnide, lidocaïne) appeared to be responsible for an increase in mortality, when used to treat ventricular arrhythmias occurring after or during infarction. Experimentally, in pigs whose rate of ventricular beats was kept constant by pacing, all the studied class I antiarrhythmic drugs, disopyramide, lidocaïne and flecaïnide, proved to be to a variable degree capable of shortening time to onset of fibrillation (TOF) elicited by controlled myocardial ischemia. Fibrillation occurred at the end of the decline, under the influence of ischemia, of electrical fibrillation threshold (EFT) down to near 0 mA. The fall of EFT to this level was checked by ischemias of increasing duration to be hastened by the cited antiarrhythmic drugs. In other words, these drugs exert a profibrillatory effect in the ischemic heart.lld:pubmed
pubmed-article:7878603pubmed:languagefrelld:pubmed
pubmed-article:7878603pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7878603pubmed:citationSubsetIMlld:pubmed
pubmed-article:7878603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7878603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7878603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7878603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7878603pubmed:statusMEDLINElld:pubmed
pubmed-article:7878603pubmed:issn0040-5957lld:pubmed
pubmed-article:7878603pubmed:authorpubmed-author:FreyszMMlld:pubmed
pubmed-article:7878603pubmed:authorpubmed-author:FauconGGlld:pubmed
pubmed-article:7878603pubmed:authorpubmed-author:AupetitJ FJFlld:pubmed
pubmed-article:7878603pubmed:authorpubmed-author:TimourQQlld:pubmed
pubmed-article:7878603pubmed:authorpubmed-author:Barral-Cadièr...lld:pubmed
pubmed-article:7878603pubmed:authorpubmed-author:Loufoua-Mound...lld:pubmed
pubmed-article:7878603pubmed:issnTypePrintlld:pubmed
pubmed-article:7878603pubmed:volume49lld:pubmed
pubmed-article:7878603pubmed:ownerNLMlld:pubmed
pubmed-article:7878603pubmed:authorsCompleteYlld:pubmed
pubmed-article:7878603pubmed:pagination349-53lld:pubmed
pubmed-article:7878603pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:meshHeadingpubmed-meshheading:7878603-...lld:pubmed
pubmed-article:7878603pubmed:articleTitle[Demonstration of the fibrillatory effect of class I anti-arrhythmia agents based on the time of fibrillation onset and electrical threshold in myocardial ischemia].lld:pubmed
pubmed-article:7878603pubmed:affiliationDépartement de Pharmacologie Médicale, Université Cl-Bernard, Lyon.lld:pubmed
pubmed-article:7878603pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7878603pubmed:publicationTypeEnglish Abstractlld:pubmed